Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

AstraZeneca
Colorcon
McKesson
Johnson and Johnson
Merck
Express Scripts

Last Updated: October 16, 2019

DrugPatentWatch Database Preview

Details for Patent: 8,431,154

See Plans and Pricing

« Back to Dashboard

Which drugs does patent 8,431,154 protect, and when does it expire?

Patent 8,431,154 protects DALIRESP and is included in one NDA.

This patent has fifty-two patent family members in thirty-five countries.

Summary for Patent: 8,431,154
Title:Oral dosage form containing a PDE 4 inhibitor as an active ingredient and polyvinylpyrrolidone as excipient
Abstract: Dosage forms for oral administration of a PDE 4 inhibitor whose solubility is slight are described. They contain PVP as binder.
Inventor(s): Dietrich; Rango (Constance, DE), Eistetter; Klaus (Constance, DE), Ney; Hartmut (Constance, DE)
Assignee: Takeda GmbH (Constance, DE)
Application Number:13/008,842
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 8,431,154
Patent Claim Types:
see list of patent claims
Composition; Compound; Dosage form; Process; Formulation;

Drugs Protected by US Patent 8,431,154

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Astrazeneca Pharms DALIRESP roflumilast TABLET;ORAL 022522-002 Jan 23, 2018 RX Yes No   Request a Trial   Request a Trial Y   Request a Trial
Astrazeneca Pharms DALIRESP roflumilast TABLET;ORAL 022522-001 Feb 28, 2011 AB RX Yes Yes   Request a Trial   Request a Trial Y   Request a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 8,431,154

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Germany102 07 160Feb 20, 2002
02003811Feb 20, 2002

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Express Scripts
Baxter
AstraZeneca
Johnson and Johnson
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.